Xpanded clonal T order 842-07-9 lymphocytes have led to the speculation that both CD4+ helper and CD8+ cytotoxic T cells are involved in the immunological pathophysiology of MDS [1,2,3].Recently, a separate CD4+ T-cell subset was identified on the basis of cytokine interleukin(IL)-17 [4]. This subset was subsequently named T-helper cell type17 (Th17), expressing the lineage-specific transcription factor retinoic acid receptor-related orphan receptor C (RORC) [5]. Since then, Th17 cells have entered the limelight because of their comprehensive involvement in inflammations [6]. IL-17A, a representative Th17 cytokine, has been described in various models of immune-mediated tissue injury, including rheumatoid arthritis, lupus, myeloma as well as others likely to be defined. Though Kordasti and colleagues recently showed the increased number of peripheral Th17 cells inTh22 and Th17 Cells in Different Stages of MDSlow risk MDS [7],the mechanism of cellular immune abnormalities remains unclear. Th22, capable of secreting IL-22 and tumor necrosis factor alpha (TNF-a), is a new subset of T cells clearly separated from other known Th cells [8]. This subset expresses none of interferon (IFN)-c, IL-17 cytokine, or respectively associated transcription factors T-bet and RORC [9]. Promoted by IL-6 and TNF-a, aryl hydrocarbon receptor (AHR) activation participates in priming human naive CD4+ T cells to Th22 subset [8,10]. Th22 cells have been found within the epidermal layer in prominence and regulating epidermal responses in inflammatory skin diseases [8]. In addition, Zhuang et al. have described a preferential expansion of Th22 cells which contribute to gastric cancer progression [11]. These data support the contention that Th22 cells are involved in the pathophysiology of autoimmunity and tumorigenesis. IL-22 belongs to the IL-10 family of cytokines and is primarily secreted by activated Th22 cells [12]. The expression of IL-22 in cancers and autoimmune disorders is various, with IL-17 as siblings but not twins regarding their biological characteristics. IL22 was up-regulated in skin pathology and anaplastic lymphoma kinase positive anaplastic large cell lymphoma, providing signaling directionality from the immune system to targeted tissue-resident cells [12,13,14]. Meanwhile, it was down-regulated in systemic lupus erythematosus [15]. However, within disorders such as inflammatory bowel disease (IBD), IL-22 played either protective or pathogenic role in discrepant induction by naive and memory/ effector cells [16,17]. Up to now, no data exist with regard to Th22 cells and their association with Th17 or Th1 in MDS patients. To investigate possible roles of the above in the pathophysiology of MDS, we measured the percentages of peripheral Th22, Th17, Th1, mRNA expression levels of RORC, IL-6, TNF-a and IL-23 in peripheral blood mononuclear cells (PBMCs) as well as cytokine level of IL-22 or IL-17 in peripheral blood (PB) and bone marrow (BM), and evaluated their relevance.FISH was performed to record cytogenetic karyotype regarding 5q31, 5q33, CEP7, 7q31, CEP8, 20q and CEPY. The patients were further divided into two subgroups based on International Prognostic Scoring System (IPSS) score [19], early-stage MDS (EMDS, low/intermediate-1 risk, n = 29) and late-stage MDS (LMDS, intermediate-2/high risk, n = 25). 5 BM blasts was chosen as the cut-off value delimiting fifty-six percent of MDS patients ,5 and forty-four percen t 5 . The MedChemExpress Met-Enkephalin demographic and key clinical f.Xpanded clonal T lymphocytes have led to the speculation that both CD4+ helper and CD8+ cytotoxic T cells are involved in the immunological pathophysiology of MDS [1,2,3].Recently, a separate CD4+ T-cell subset was identified on the basis of cytokine interleukin(IL)-17 [4]. This subset was subsequently named T-helper cell type17 (Th17), expressing the lineage-specific transcription factor retinoic acid receptor-related orphan receptor C (RORC) [5]. Since then, Th17 cells have entered the limelight because of their comprehensive involvement in inflammations [6]. IL-17A, a representative Th17 cytokine, has been described in various models of immune-mediated tissue injury, including rheumatoid arthritis, lupus, myeloma as well as others likely to be defined. Though Kordasti and colleagues recently showed the increased number of peripheral Th17 cells inTh22 and Th17 Cells in Different Stages of MDSlow risk MDS [7],the mechanism of cellular immune abnormalities remains unclear. Th22, capable of secreting IL-22 and tumor necrosis factor alpha (TNF-a), is a new subset of T cells clearly separated from other known Th cells [8]. This subset expresses none of interferon (IFN)-c, IL-17 cytokine, or respectively associated transcription factors T-bet and RORC [9]. Promoted by IL-6 and TNF-a, aryl hydrocarbon receptor (AHR) activation participates in priming human naive CD4+ T cells to Th22 subset [8,10]. Th22 cells have been found within the epidermal layer in prominence and regulating epidermal responses in inflammatory skin diseases [8]. In addition, Zhuang et al. have described a preferential expansion of Th22 cells which contribute to gastric cancer progression [11]. These data support the contention that Th22 cells are involved in the pathophysiology of autoimmunity and tumorigenesis. IL-22 belongs to the IL-10 family of cytokines and is primarily secreted by activated Th22 cells [12]. The expression of IL-22 in cancers and autoimmune disorders is various, with IL-17 as siblings but not twins regarding their biological characteristics. IL22 was up-regulated in skin pathology and anaplastic lymphoma kinase positive anaplastic large cell lymphoma, providing signaling directionality from the immune system to targeted tissue-resident cells [12,13,14]. Meanwhile, it was down-regulated in systemic lupus erythematosus [15]. However, within disorders such as inflammatory bowel disease (IBD), IL-22 played either protective or pathogenic role in discrepant induction by naive and memory/ effector cells [16,17]. Up to now, no data exist with regard to Th22 cells and their association with Th17 or Th1 in MDS patients. To investigate possible roles of the above in the pathophysiology of MDS, we measured the percentages of peripheral Th22, Th17, Th1, mRNA expression levels of RORC, IL-6, TNF-a and IL-23 in peripheral blood mononuclear cells (PBMCs) as well as cytokine level of IL-22 or IL-17 in peripheral blood (PB) and bone marrow (BM), and evaluated their relevance.FISH was performed to record cytogenetic karyotype regarding 5q31, 5q33, CEP7, 7q31, CEP8, 20q and CEPY. The patients were further divided into two subgroups based on International Prognostic Scoring System (IPSS) score [19], early-stage MDS (EMDS, low/intermediate-1 risk, n = 29) and late-stage MDS (LMDS, intermediate-2/high risk, n = 25). 5 BM blasts was chosen as the cut-off value delimiting fifty-six percent of MDS patients ,5 and forty-four percen t 5 . The demographic and key clinical f.
